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SCIENTIFIC OPINION 
Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic 
acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid 
(DPA)
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to deliver a scientific opinion on the Tolerable Upper Intake Level (UL) of the n-3 LCPUFAs 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). Available data 
are insufficient to establish a UL for n-3 LCPUFA (individually or combined) for any population group. At 
observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse effects in healthy 
children or adults. Long-term supplemental intakes of EPA and DHA combined up to about 5 g/day do not 
appear to increase the risk of spontaneous bleeding episodes or bleeding complications, or affect glucose 
homeostasis immune function or lipid peroxidation, provided the oxidative stability of the n-3 LCPUFAs is 
guaranteed. Supplemental intakes of EPA and DHA combined at doses of 2-6 g/day, and of DHA at doses of 
2-4 g/day, induce an increase in LDL-cholesterol concentrations of about 3 % which may not have an adverse 
effect on cardiovascular disease risk, whereas EPA at doses up to 4 g/day has no significant effect on LDL 
cholesterol. Supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and supplemental intakes 
of EPA alone up to 1.8 g/day, do not raise safety concerns for adults. Dietary recommendations for EPA and 
DHA based on cardiovascular risk considerations for European adults are between 250 and 500 mg/day. 
Supplemental intakes of DHA alone up to about 1 g/day do not raise safety concerns for the general population. 
No data are available for DPA when consumed alone. In the majority of the human studies considered, fish oils, 
also containing DPA in generally unknown (but relatively low) amounts, were the source of EPA and DHA. 
© European Food Safety Authority, 2012. 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to deliver a scientific opinion on the Tolerable Upper Intake Level of 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). 
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) contain one of the double bonds located at three 
carbon atoms from the methyl end. The main n-3 PUFAs in the diet are -linoleic acid (ALA; 
18:3Δ9c,12c,15c), eicosapentaenoic acid (EPA; 20:5Δ5c,8c,11c,14c,17c), docosahexaenoic acid 
(DHA; 22:6Δ4c,7c,10c,13c,16c,19c ) and docosapentaenoic acid (DPA; 22:5Δ7c,10c,13c,16c,19c). 
EPA, DHA and DPA are n-3 long-chain PUFAs (n-3 LCPUFA), i.e. n-3 PUFA with 20 or more 
carbon atoms. The n-3 LCPUFAs are important structural components of cell membranes and 
contribute to various membrane functions such as fluidity, permeability, activity of membrane-bound 
enzymes and receptors, and signal transduction. 
Fish is a uniquely rich source of n-3 LCPUFAs. Other natural sources are human milk, cultivated 
marine algae, marine mammals and krill. EPA, DHA and DPA may also be provided by foods and 
supplements enriched with n-3 LCPUFAs (e.g. fish oils, single cell oils, krill oils added to foods or 
consumed as food supplements). The ratios of EPA:DHA:DPA differ between the various sources of 
n-3 LCPUFAs, although DPA is generally a minor quantitative component compared to EPA and 
DHA. Food supplements containing mainly EPA, or mainly DHA (isolated from microalgae), are also 
available. Pure DPA is not commercialised for human consumption. 
Adverse effects, which have been described in humans in association with high intakes of EPA and 
DHA, include bleeding episodes, impaired immune function, increased lipid peroxidation, and 
impaired lipid and glucose metabolism. However, no tolerable upper intake level (UL) for EPA, DHA 
or DPA has been set by any authoritative body. 
Previous assessments on the safety of n-LCPUFAs referred to mixtures of EPA and DHA (DPA was 
not explicitly mentioned), and were primarily based on a large number of human studies. The Panel 
considers that the evaluation of the safety of n-3 LCPUFA intakes should be based on the human 
studies available.  
The majority of human intervention studies which have investigated the effects of n-3 LCPUFAs on 
different health outcomes have used fish oils containing known amounts of EPA and DHA and 
generally unknown (but relatively low) amounts of DPA; EPA and DHA in combination as ethyl 
esters; or more rarely mostly EPA or mostly DHA. Very few studies are available using krill oil as a 
source of EPA and DHA, and no studies have been conducted with sources containing mainly DPA, 
or with DPA alone. 
Long-term human intervention studies which have investigated the effects of supplemental intakes of 
EPA and DHA, either alone or in combination, at doses up to about 1 g/day on a variety of health 
outcomes (e.g., cardiovascular, neurological, immunological), have generally reported no adverse 
effects in relation to the consumption of EPA or DHA at these doses. 
Long-term supplemental intakes of EPA and DHA combined up to about 5 g/day do not increase the 
risk of spontaneous bleeding episodes or bleeding complications even in subjects at high risk of 
bleeding (e.g. taking acetylsalicylic acid or anti-coagulants).  
Supplemental intakes of EPA and DHA combined at doses up to 5 g/day consumed for up to 
12 weeks do not significantly affect glucose homeostasis in healthy or diabetic subjects, nor do they 
induce changes in immune functions which might raise concern in relation to the risk of infections or 
inappropriate activation of inflammatory responses. The data available are insufficient to conclude on 
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whether the same doses administered mostly as EPA or mostly as DHA would have different effects 
on these outcomes.  
Supplemental intakes of EPA and DHA consumed either alone or in combination at doses up to about 
5 g/day for up to 16 weeks do not induce changes in lipid peroxidation which might raise concern in 
relation to cardiovascular disease (CVD) risk as long as the oxidative stability of these n-3 LCPUFA 
is guaranteed.    
Supplemental intakes of EPA and DHA combined of 2-6 g/day, and supplemental intakes of mostly 
DHA of 2-4 g/day, increase blood concentrations of LDL cholesterol by about 3 %. Such increase is 
accompanied by a decrease in triglycerides with no changes in total (or non-HDL) cholesterol 
concentrations. Supplemental intakes of mostly EPA at doses up to 4 g/day have no significant effect 
on LDL-cholesterol concentrations. The Panel considers that the small increase in LDL-cholesterol 
concentrations associated with combined EPA and DHA supplementation or with DHA 
supplementation alone at the doses mentioned above may not have an adverse effect on CVD risk.  
The Panel concludes that the available data are not sufficient to establish a tolerable upper intake 
level for n-3 LCPUFA (DHA, EPA, and DPA, individually or combined) for any population group. 
At observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse effects 
in healthy children or adults.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, 
and supplemental intakes of EPA alone up to 1.8 g/day, do not raise safety concerns for the adult 
population. Limited data are available on the effects of long-term supplementation with these n-3 
LCPUFAs at higher doses. The Panel also notes that observed intakes of EPA and DHA from food 
and food supplements in European populations are generally below these amounts. Dietary 
recommendations for EPA and DHA based on CVD risk considerations for European adults are 
between 250 and 500 mg/day. There are no specific recommendations for EPA. 
The Panel also considers that supplemental intakes of DHA alone up to about 1 g/day do not raise 
safety concerns for the general population. Limited data are available on the effects of long-term 
supplementation with DHA alone at higher doses. The Panel notes that specific dietary 
recommendations for DHA for European adults and children are well below this amount.  
No data are available for DPA when consumed alone. The Panel notes that in the majority of the 
human studies considered, fish oils, which also contained DPA in generally unknown (but relatively 
low) amounts, were the source of EPA and DHA. No dietary recommendations have been made 
specifically for DPA. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Several Member States have raised concerns about a potential link between the intake of omega-3 
long chain polyunsaturated fatty acids (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), 
docosapentaenoic acid (DPA)) and adverse health effects. 
The scientific opinion of the European Food Safety Authority of 6 July 2005
4
 on nutrition claims 
concerning omega-3 fatty acids refers to the reporting of adverse effects of high consumption of 
omega-3 polyunsaturated fatty acids and these effects include prolonged bleeding time and increased 
tendency to nasal bleeding, suppression of certain immune reactions which enable the body to attack 
pathogens and adverse effects on oxidation of LDL cholesterol. 
Scientific opinions of the European Food Safety Authority on the substantiation of health claims 
related to EPA and DHA have proposed intakes of EPA and DHA of about 2-4 g/day in order to 
obtain the claimed effects
5
. 
In the absence of EU advice on a tolerable upper intake level, the German Federal Risk Assessment 
Agency has established a level of 1.5 g/day as the recommended upper intake level for omega-3 
polyunsaturated fatty acids. The US Food and Drug Administration (FDA) has recommended not to 
exceed an intake of 3 g/day of omega-3 fatty acids (EPA and DHA) as a safeguard against possible 
adverse effects of these fatty acids.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002 of the European Parliament and 
of the Council of 29 January 2002 laying down the general principles and requirements of food law, 
establishing the European Food Safety Authority and laying down procedures in matters of food 
safety
6
, the European Commission asks the European Food Safety Authority to: 
Review the existing scientific data on the possible link between the intake of omega-3 long-chain 
polyunsaturated fatty acids (DHA, EPA, DPA) and adverse health effects in the general population 
and, as appropriate in specific vulnerable subgroups of the population. 
Provide advice on a tolerable upper intake level (UL) for omega-3 long-chain polyunsaturated fatty 
acids (DHA, EPA, DPA) individually or combined for the general population and, as appropriate, for 
vulnerable subgroups of the population.  
In the absence of tolerable upper intake level, to provide advice on a daily intake of omega-3 
long-chain polyunsaturated fatty acids (DHA, EPA, DPA) either individually or combined and which 
does not give rise to concerns about adverse health effects. 
                                                     
4  The EFSA Journal 2005; 253, 1-29.  
5  EFSA Journal 2009; 7(9):1263; EFSA Journal 2010;8(10):1734; EFSA Journal 2010;8(10):1796 
6  OJ. L 31, 1.2.2002, p.1-24. 
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ASSESSMENT 
1. Introduction 
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) contain one of the double bonds located at three 
carbon atoms from the methyl end. The main n-3 PUFAs in the diet are -linoleic acid (ALA; 
18:3Δ9c,12c,15c), eicosapentaenoic acid (EPA; 20:5Δ5c,8c,11c,14c,17c), docosahexaenoic acid 
(DHA; 22:6Δ4c,7c,10c,13c,16c,19c ) and docosapentaenoic acid (DPA; 22:5Δ7c,10c,13c,16c,19c). 
The n-3 PUFAs EPA, DHA and DPA are usually referred to as n-3 long-chain PUFAs 
(n-3 LCPUFAs), i.e. n-3 PUFA with 20 or more carbon atoms. The n-3 LCPUFAs are important 
structural components of cell membranes and contribute to various membrane functions such as 
fluidity, permeability, activity of membrane-bound enzymes and receptors, and signal transduction. 
Adverse effects, which have been described in humans in association with high intakes of n-3 
LCPUFA, include bleeding episodes, impaired immune function, increased lipid peroxidation, and 
impaired lipid and glucose metabolism. However, no tolerable upper intake level (UL) for EPA, DHA 
or DPA has been set by any authoritative body.  
In 1997, the US Food and Drug Administration (FDA, 1997) concluded that total intakes (from diet 
and supplements) of EPA and DHA up to 3 g/day were generally recognised as safe (GRAS). This 
figure was set on the basis of increased bleeding times, increased fasting blood glucose concentrations 
in non-insulin dependent, type 2 diabetic subjects, and increased LDL-cholesterol concentrations, 
particularly in hypertriglyceridaemic or hypercholesterolaemic subjects, at higher levels of intake.   
In 2004, the FDA approved a mixture of EPA and DHA in the form of ethyl esters as a registered drug 
for the treatment of hypertriglyceridaemia in adult patients at doses of 4 g/day. No significant adverse 
effects were reported for the drug vs. placebo in human intervention studies at this dose.  
In 2005, the US Institute of Medicine (IoM, 2005) also evaluated the safety of n-3 LCPUFA and 
concluded that the available data were insufficient to set a UL for EPA and DHA, although subjects 
with impaired glucose tolerance or type 2 diabetes and subjects with familial hypercholesterolemia 
using anticoagulants were recommended to consume EPA and DHA supplements with caution. The 
bases of this recommendation are not explicitly stated.   
In May 2009, the German Federal Risk Assessment Agency (BfR, 2009) recommended that 1.5 g/day 
of EPA and DHA from all sources should not be exceeded and this recommendation was based on the 
increased risk of bleeding reported in one study in children (Clarke et al., 1990). 
In June 2011, the Norwegian Scientific Committee for Food Safety (VKM, 2011) conducted a safety 
evaluation of n-3 LCPUFA from all sources. Previous evaluations by other authoritative bodies and an 
up to date review of the literature available up to March 2009 were taken into account. No clear 
adverse effects were associated with EPA and DHA intakes up to 6.9 g/day and no UL could be 
established.  
The Panel notes that the conclusions of all these safety assessments referred to mixtures of EPA and 
DHA (DPA was not explicitly mentioned) and were primarily based on a large number of human 
studies.   
The Panel considers that the evaluation of the safety of n-3 LCPUFA intakes should be based on the 
human studies available.  
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2. Nutritional background 
2.1. Food sources including dietary supplements 
Fish is a uniquely rich source of n-3 LCPUFA (EFSA (European Food Safety Authority), 2005). 
Other natural sources are human milk, cultivated marine algae, marine mammals and krill. EPA, DHA 
and DPA may also be provided by foods and supplements enriched with n-3 LCPUFAs (e.g., fish oils, 
single cell oils, krill oils added to foods or consumed as food supplements). The ratios of 
EPA:DHA:DPA differ between the various sources of n-3 LCPUFAs, although DPA is generally a 
minor quantitative component compared to EPA and DHA. Food supplements containing mainly 
EPA, or mainly DHA (isolated from microalgae), are also available. Pure DPA is not commercialised 
for human consumption. 
The n-3 LCPUFAs are present in foods and food supplements mainly as triacylglycerols (TAGs), and 
as free fatty acids or bound to phospholipids in smaller amounts. EPA and DHA may be found in the 
form of ethyl esters in synthetically produced concentrated supplements. In krill, EPA and DHA are 
mainly bound to phospholipids.   
Lipid peroxidation may occur during the processing and storage of foods and food supplements rich in 
n-3 LCPUFA in the absence of appropriate amounts of antioxidants (e.g. vitamin E).  
2.2. Dietary intakes 
Mean intakes of n-3 LCPUFA in European countries vary according to sex, age group, and 
supplementation habits (Appendices A, B and C). There is a large diversity in the methodology used 
to assess the individual intakes of children, adolescents and adults. These differences in dietary 
assessment methods make direct comparisons difficult. Age classifications may not be uniform and 
comparability is also hindered by differences in food composition tables used for the conversion of 
food consumption data to nutrient intake data (Deharveng et al., 1999). Although these differences 
have an impact on the accuracy of between-country comparisons, the data presented give a rough 
overview of average intakes and intakes in high consumers of n-3 LCPUFA in a number of European 
countries.  
References were selected in order to obtain data on intake distributions and/or high consumption of 
n-3 LCPUFA individually or collectively in national surveys, in large cohorts and/or in populations of 
fish consumers.   
2.2.1. Adults 
2.2.1.1. EPA 
Mean daily intakes of EPA from food only were between 50 mg/day (Spain, both sexes, occasional 
fish consumers, 35-65 years) and 150 mg/day (France, men, 45 years), and median daily intakes 
between 14 mg/day (Belgium, women, 18-39 years) and 180 mg/day (Denmark, men, 50-64 years). 
Data from surveys considering food and food supplements combined reported slightly higher mean 
daily intakes of EPA in the general adult population (up to 330 mg/day, Norway, 16-79 years). Daily 
intakes of EPA from food only in the highest percentiles of consumption (P95) from the few surveys 
which reported on this outcome were between 308 mg/day (France, women, 35 years) and 
428 mg/day (Belgium, women, 18-39 years). The high percentiles available for Denmark (P75) were 
within that range. In high seafood consumers, mean daily intakes from food only ranged from 
320 mg/day (Spain, 35-65 years) to 991 mg/day (France, 18 years, fifth quintile of EPA-DHA 
intake). No surveys reported on EPA intakes from food and supplements combined in high seafood 
consumers. 
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2.2.1.2. DHA 
Mean daily intakes of DHA from food only were between 131 mg/day (Belgium, women, 
18-39 years) and 273 mg/day (France, men, 45 years), and median daily intakes between 
42.5 mg/day (Belgium, women, 18-39 years) and 430 mg/day (Denmark, men, 50-64 years). Data 
from surveys considering food and food supplements combined reported higher mean daily intakes of 
DHA in the general adult population (up to 490 mg/day, Norway, 16-79 years). Daily intakes of DHA 
in the highest percentiles of consumption (P95) for the few surveys reporting on this outcome were 
between 574 mg/day (France, women, 35 years) and 668 mg/day (France, men, 45 years) from food 
only. The high percentiles available for Denmark (P75) were within that range. Mean daily intakes in 
high seafood consumers from food only were between 600 mg/day (Finnish, women, 18 years) and 
1,709 mg/day (France, 18 years, fifth quintile of EPA-DHA intake). No surveys reported on DHA 
intakes from food and supplements combined in high seafood consumers. 
2.2.1.3. DPA 
Mean daily intakes of DPA from food only were between 25 mg/day (Belgium, women, 18-39 years) 
and 75 mg/day (France, men, 45 years), and median daily intakes between 12 mg/day (Belgium, 
women, 18-39 years) and 80 mg/day (Denmark, men, 50-64 years). Daily intakes of DPA from food 
only in the highest percentiles of consumption (P95) from the few surveys which reported on this 
outcome were between 100 mg/day (Belgium, women, 18-39 years) and 138 mg/day (France, men, 
45 years). The high percentiles available for Denmark (P75) were within that range. Data from food 
and food supplements combined were within these ranges. Mean daily intakes in high seafood 
consumers from food only were up to 129 mg/day (France, men, 18-64 years).  
2.2.1.4. EPA and DHA/total n-3 LCPUFA 
Mean daily intakes of EPA and DHA from food only were between 127 mg/day (Germany, women, 
18-24 years) and 295 mg/day (Germany, men, 45-54 years). Daily intakes of EPA and DHA in the 
highest percentiles of consumption (P95) were between 285 mg/day (The Netherlands, women, 
19-30 years) and 1,115 mg/day (Belgium, women, 18-39 years), going up to 1,278 mg/day (Ireland, 
51-64 years) when food and food supplements were considered together. Mean intakes of EPA and 
DHA in high fish consumers from food only were up to 2,700 mg/day (France, 18 years, fifth 
quintile of EPA-DHA intake). No surveys reported on EPA and DHA intakes from food and 
supplements combined in high seafood consumers. 
Mean daily intakes of EPA, DHA and DPA were about 400-500 mg/day (France, women 35 years 
and males 45 years), increasing to 2,570 mg/day (Norway, males, 16-79 years, fourth quartile of 
n-3 LCPUFA) when food and food supplements were considered together. Data from another survey 
considering food and fish oil combined for total n-3 LCPUFA were within these ranges. 
2.2.2. Children 
No population-based data were available for infants.  
2.2.2.1. Young children (1-3 years) 
Intake data were available for Germany (EPA and DHA from food only excluding fortified food) and 
Norway (EPA, DHA and DPA considering also food supplements).  
Mean daily intakes of EPA and DHA in German girls and boys, aged 2 to  4 years consuming fish 
were 100 to 118 mg/day. Mean intakes of EPA, DHA and DPA in Norwegian children aged 1 or 
2 years were 400-600 mg/day (95
th
 percentiles 1,400-1,700 mg/day).  
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2.2.2.2. Children aged 3-13 years 
Data from food and food supplements combined were available for this age group for individual fatty 
acids (Sweden), for EPA and DHA combined (The Netherlands), and for EPA, DHA and DPA 
combined (Norway). Mean daily intakes in German fish consumers in a survey which considered 
intake of EPA and DHA from food only and excluding fortified foods have been reported to be lower 
than the high consumers (95
th
 percentile) in surveys considering food and food supplements. 
Mean daily intakes of EPA in Swedish children (4-12 years) were 40 mg/day, and the 95
th
 percentiles 
of intake varied between 140 mg/day (4 years) and 170 mg/day (8-9 years).  
Mean daily intakes of DHA in this population subgroup were between 100 mg/day (4 years) and 
120 mg/day (8-12 years). The 95
th
 percentiles of intake were between 320 mg/day (4 years) and 
420 mg/day (8-12 years).  
Mean daily intakes of DPA were between 30 mg/day (4 years) and 40 mg/day (8-12 years), and the 
95
th
 percentiles of intake varied from 70 mg/day (4 years) to 90 mg/day (8-12 years).  
In Dutch children (7-13 years), median daily intakes of EPA and DHA were between 62 mg/day (boys 
7-8 years) and 66 mg/day (girls 7-13 years). Higher percentiles of intake (P95) were between 
264 mg/day (girls, 9-13 years) and 317 mg/day (boys, 9-13 years). Mean daily intakes of EPA, DHA 
and DPA in Norwegian children aged 4-9 years were 300-400 mg/day, and the 95
th
 percentiles were 
1,200-1,400 mg/day. 
2.2.2.3. Adolescents (13-19 years) 
Data for the individual fatty acids EPA, DPA and DHA from food only were available from Belgium 
in children of both sexes aged 13-18 years. For DHA, mean daily intakes were 111 mg/day, and the 
95
th
 percentile was 363 mg/day. Mean daily intakes for EPA was 56 mg/day, and the 95
th
 percentile 
was 244 mg/day. Mean daily intakes for DPA were 18 mg/day, and the 95
th
 percentile was 63 mg/day.  
The highest mean daily intakes of EPA and DHA combined from food (excluding fortified food) were 
reported in German fish consumers aged 13-14 years (girls, 214 mg/day) and 15-18 years (boys, 
324 mg/day) which increased up to 536 mg/day and 838 mg/day, respectively, on days of fish 
consumption. Data in Dutch children from food and supplements combined were lower.  
In Norwegian adolescents aged 13 years, mean intakes for EPA, DHA and DPA combined from food 
only were 200 mg/day (95
th
 percentiles of 700 mg/day), and 300 mg/day (95
th
 percentile was 
1,100 mg/day) when food and food supplements were considered. 
2.2.3. Summary of intake data 
The Panel notes that mean daily intakes of n-3 LCPUFA in adults at the highest percentiles of intake 
were generally <1,200 mg/day from food only, and <1,300 mg/day when food supplements were 
considered as well. In high fish consumers daily intakes of n-3 LCPUFA from food only were 
<2.7g/day. No surveys reported on EPA and DHA intakes from food and supplements combined in 
high seafood consumers. 
In children, the highest intakes of n-3 LCPUFA were observed in children aged 1-2 years consuming 
food supplements (95
th
 percentiles 1,400-1,700 mg/day).   
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2.3. Digestion and absorption 
Triacylglycerols represent the major dietary form of n-3 LCPUFA, where three fatty acids are 
esterified to a glycerol backbone and represent more than 90 % by weight. Owing to the asymmetric 
structure of substituted glycerol, the esterified fatty acids are distinguished by their position, namely 
the sn-1, sn-2 and sn-3 position. Considering their metabolic fate (action of lipases) in the digestive 
tract, sn-1 and sn-3-esterified fatty acids are considered as esterified at “external” positions, whereas 
the sn-2 position is considered as “internal”.  
TAGs undergo lipolysis by lipases in the gastrointestinal tract prior to absorption. Although there are 
lipases in the saliva and gastric secretion, most lipolysis occurs in the small intestine (IoM, 2005). In 
the intestine, TAGs are emulsified with bile salts and phospholipids secreted into the intestine in bile, 
hydrolysed by pancreatic enzymes, and almost completely absorbed. Pancreatic lipase has a high 
specificity for the sn-1 and sn-3 position of dietary triacylglycerols so that free fatty acids from the 
sn-1 and sn-3 position and 2-monoacylglycerol are released for absorption. The pancreatic lipase also 
completely hydrolyses  ethyl esters into fatty acids and the ethanol backbone, although the affinity of 
the lipase for the fatty acid-ethanol bond appears to be lower than for the fatty acid-glycerol bond. 
Dietary phospholipids are hydrolysed by pancreatic phospholipase A2 prior to absorption.  
Dietary EPA and DHA are absorbed into the enterocyte as free fatty acids or 2-monoacylglycerol, 
where they are incorporated into TAGs. The TAGs are then assembled together with cholesterol, 
phospholipids, and apoproteins into chylomicrons, which enter the circulation. Data are scarce for 
DPA, but there is no reason to assume that digestion and absorption of DPA might be different from 
EPA and DHA. 
Both comparable and lower rates of absorption and incorporation of EPA and DHA into cell 
membranes and tissues have been reported for ethyl esters compared to TAGs. Conversely, higher 
rates of absorption and incorporation of EPA and DHA into cell membranes and tissues have been 
reported for phospholipids compared to TAGs. However, as the safety assessment of EPA, DHA and 
DPA refers to long-term consumption and these fatty acids are absorbed almost completely regardless 
of the source, the Panel considers that there is no need to undertake separate safety assessments for 
different sources of n-3 LCPUFA. This Opinion refers to EPA, DHA and DPA from all sources.  
2.4. Metabolism 
Circulating n-3 LCPUFAs are either used as a source of energy (i.e. oxidised to carbon dioxide and 
water), incorporated into tissue lipids, or utilised in eicosanoid synthesis. Small amounts are lost 
during sloughing of skin and other epithelial cells (IoM, 2005). 
ALA is essential in human nutrition as a precursor for n-3 LCPUFA. EPA, DPA and to a lesser degree 
DHA are synthesised from ALA through the sequential action of various desaturases and elongases in 
animal tissues, but not in plants. Estimates for the conversion of ALA into EPA, DPA and DHA are 
low, and even lower when dietary intakes of these n-3 LCPUFAs are high (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010). The Panel notes that endogenous production of EPA, 
DPA and DHA from ALA may be negligible compared to the doses used in the studies considered for 
the assessment of the safety of these n-3 LCPUFAs.   
DHA is a component of membrane structural lipids, especially of phospholipids in nervous tissue and 
the retina. EPA can be transformed to eicosanoids, a group of biologically active substances including 
prostaglandins, prostacyclins and leukotrienes which participate in the regulation of blood pressure, 
renal function, blood coagulation, inflammatory and immunological reactions and other functions in 
tissues; EPA is also the precursor for series 3 prostanoids and series 5 leukotrienes (Kinsella et al., 
1990). Other metabolites of EPA and DHA (resolvins, protectins) are thought to be involved in the 
resolution of the inflammatory response. Both EPA and DHA are incorporated into cell membranes, 
and thus may impact cellular metabolism, signal transduction, and regulation of gene expression. 
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Although DPA can be retro-converted to EPA and only minimally to DHA, little is known about the 
biological effects of DPA in vivo (Kaur et al., 2011). As acyl chain length and degree of saturation 
may affect the function of fatty acids in biological membranes, it is expected that alterations in the 
content of these fatty acids will differentially affect membrane structure and function. Indeed, 
different effects of EPA, DHA and DPA on enzyme activity, gene expression and platelet aggregation 
have been described in vitro (Kaur et al., 2011; VKM, 2011). However, the exact molecular and 
cellular effects of each of the n-3 LCPUFA, and their impact on disease outcomes in vivo, are not 
precisely known. 
High dietary intakes of EPA and DHA result in decreased tissue concentrations of arachidonic acid 
(AA) and increased concentrations of EPA and DHA, respectively. Supplementation with DHA is 
also accompanied by an increase in EPA, which could be explained by retroconversion of DHA to 
EPA or by inhibition of further metabolism of the EPA formed from ALA. These effects of DHA 
supplementation induce changes in AA metabolism and in the balance of eicosanoids synthesized 
from the n-6 and n-3 fatty acids, and thus may have an impact on the functions partially regulated by 
eicosanoids cited above (IoM, 2005).  
The Panel notes that although endogenous inter-conversion of EPA, DPA and DHA may occur 
in vivo, and particularly when either fatty acid (mainly EPA and DHA) is administered in isolation at 
high doses, this inter-conversion is considered to be negligible when they are administered in 
combination at the dose levels used in the studies considered for the assessment of their safety. The 
Panel also notes that different biological effects of EPA, DPA and DHA cannot be excluded, and that 
the effects of these n-3 LCPUFAs may depend on the mode of administration (e.g., given alone vs. 
given in combination).  
2.5. Requirements and dietary reference values 
ALA is an essential fatty acid required to maintain metabolic integrity and is a precursor of EPA, 
DPA and to a lesser degree DHA. Whereas some authoritative bodies and organisations have set 
dietary recommendations for total n-3 PUFAs (primarily ALA, EPA, DHA and DPA in combination) 
for different population subgroups, or for ALA as the essential precursor of EPA, DPA and DHA 
(IoM, 2005), many authorities have separate recommendations for ALA on the one hand, and for the 
n-3 LCPUFAs (either as total n-3 LCPUFAs or as EPA and DHA) on the other hand, owing to the 
different biological functions attributed to ALA and to the n-3 LCPUFAs (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2009, 2010). 
Dietary recommendations from national and international bodies for n-3 LCPUFAs (mostly as EPA 
and DHA) range from 200 mg to >600 mg/day for adults (Table 1), and from 40 mg to 250 mg/day for 
infants older than six months and for children and adolescents (Table 2). These recommendations 
have been generally based on the inverse relationship observed between the consumption of these n-3 
LCPUFAs (primarily from fish and fish oils) and a lower risk of coronary artery disease.  
Specific recommendations have also been made for DHA for infants and young children (6 to 
24 months of age) ranging from 70-100 mg/day based on its accumulation in the central nervous 
system and its effects on visual function during the complementary feeding period (Table 2) and for 
additional DHA (100-200 mg/day) for pregnant and lactating women to compensate for oxidative 
losses of maternal dietary DHA and accumulation of DHA in body fat of the fetus/infant (Table 1).  
The Panel notes that the highest dietary recommendations for EPA and DHA (mostly as EPA and 
DHA or as DHA alone) for different population subgroups are 610 mg/day (Australia). The Panel also 
notes that the highest recommendations for EPA and DHA combined for European adults and 
children (250-500 mg/day) are based on the reduction of CVD risk, and that no dietary 
recommendations have been made specifically for DPA. 
Tolerable Upper Intake Level of EPA, DHA and DPA 
 
12 EFSA Journal 2012;10(7):2815 
Table 1:  Recommended dietary intakes for n-3 polyunsaturated fatty acids from national and 
international bodies (adults)
1
. 
National/International Body 
n-3 PUFA ALA EPA+DHA
2
 
% of 
energy 
g/day 
% of 
energy 
g/day 
% of 
energy 
mg/day 
(WHO/FAO, 2003) 1-2 - - - - 200-1000/wk 
United Kingdom, 
(DoH, 1991, 1994) 
- - >0.2 - - 200 
(SACN, 2004) - - - - - 450 
(Eurodiet, 2000) - - - 2 - 200 
Belgium, Superior Health Council 
(CSS, 2009; SHC, 2004) 
1.3-2.0 - >1 - 0.3  
Australia, (Ministry of Health-
Department of Health and Ageing - 
National Health and Medical 
Research Council, 2006) 
      
     Adult men - - - 1.3 - 610
3
 
     Adult women - - - 0.8 - 430
3
 
     Pregnancy - - - 1.0 - 115
4
 
     Lactation - - - 1.2 - 145
4
 
The Netherlands,  
(Health Council, 2001, 2006) 
- - 1 - - 450 
Nordic Countries, (NNR, 2004) 1 - - - - - 
France, (ANSES, 2010)   1   500 (250 DHA) 
USA, (IoM, 2005)       
     Adult men - - - 1.6 - - 
     Adult women - - - 1.1 - - 
     Pregnancy - - - 1.4 - - 
     Lactation - - - 1.3 - - 
Germany, Austria, Switzerland,  
(D-A-CH, 2012) 
- - 0.5 - - - 
     Pregnancy - - - - - 200 (DHA) 
     Lactation - - - - - 200 (DHA) 
(EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 
2010) 
  0.5   250 
    Pregnancy and lactation      +100-200 (DHA) 
1 Values for pregnancy and lactation are only indicated if different from those for adult women. 2Values in bold refer to n-3 
LCPUFA (EPA, DHA and DPA); 3Suggested Dietary Target; 4 Adequate Intakes. 
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Table 2:   Recommended dietary intakes for n-3 polyunsaturated fatty acids from national and 
international bodies (children). 
National/International Body 
n-3 PUFA ALA EPA+DHA
1
 
% of 
energy 
g/day 
% of 
energy 
g/day 
% of energy 
mg/day 
United Kingdom,  
(DoH, 1991, 1994) 
- - 0.2  - - 
     5 years - - - - - 200 
Belgium, Superior Health 
Council, (CSS, 2009) 
      
      0-12 mo - - - 0.5 - - 
         >1 y - - 0.45-1.50 - 0.1-0.4 DHA 
0.05-0.15 EPA 
- 
Australia, (Ministry of Health-
Department of Health and Ageing 
- National Health and Medical 
Research Council, 2006) 
      
      0-1 y - 0.5 - - - - 
      1-3 y - - - 0.5 - 40 
      4-8 y - - - 0.8 - 55 
    9-13 y boys - - - 1.0 - 70 
               girls - - - 0.8 - 70 
  14-18 y boys - - - 1.2 - 125 
               girls - - - 0.8 - 85 
The Netherlands, (Health 
Council, 2001) 
      
 
   0-5 mo - - - 0.08/kg - 20/kg (DHA) 
   6 mo-18 y - - 1 - - 150-200 
Nordic Countries, (NNR, 2004) 1 - - - - - 
France, (ANSES, 2010)       
     0-6 mo - - 0.45 - - DHA: 0.32 % 
of total FAs, 
EPA<DHA 
     6 mo-3y - - 0.45 - - 70 (DHA) 
     3-9 y - - 1 - - 250 (125 DHA) 
  10-18 y - - 1 - - 500 (250 DHA) 
USA, (IoM, 2005)       
      0-6 mo - 0.5     
      7-12 mo - 0.5     
      1-3 y - - - 0.7 - - 
      4-8 y - - - 0.9 - - 
    9-13 y boys - - - 1.2 - - 
               girls - - - 1.0 - - 
  14-18 y boys - - - 1.6 - - 
               girls - - - 1.1 - - 
Germany, Austria, Switzerland, 
(D-A-CH, 2012) 
- - 0.5 - - - 
(EFSA Panel on Dietetic 
Products Nutrition and Allergies 
(NDA), 2010) 
      
      7-24 mo - - 0.5 - - 100 (DHA) 
      2-18 y - - 0.5 - - 250 
1Values in bold refer to n-3 LCPUFA (EPA, DHA and DPA). 
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3. Hazard identification 
Adverse effects which have been described in humans in association with high intakes of n-3 
LCPUFA include bleeding episodes, impaired immune function, increased lipid peroxidation, and 
impaired lipid and glucose metabolism.  
The majority of human intervention studies which have investigated the effects of n-3 LCPUFA on 
different health outcomes have used fish oils containing known amounts of EPA and DHA and 
generally unknown (but relatively low) amounts of DPA; EPA and DHA in combination as ethyl 
esters; or more rarely EPA alone or DHA alone. Very few studies are available using krill oil as a 
source of EPA and DHA, and no studies have been conducted with sources containing mainly DPA or 
with DPA alone.  
Long-term human intervention studies which have investigated the effects of supplemental intakes of 
EPA and DHA, either alone or in combination, at doses up to about 1 g/day on a variety of health 
outcomes (e.g. cardiovascular, neurological and immunological) have generally reported no adverse 
effects in relation to the consumption of EPA or DHA at these dose levels. 
3.1. Bleeding complications, bleeding time and platelet function 
3.1.1. Bleeding complications 
An increased tendency to bleed from the nose and urinary tract, and an increased mortality from 
haemorrhagic stroke, have been reported in Greenlandic Inuits with high intakes of fatty fish (mean 
intakes of n-3 LCPUFA about 6.5 g/day), as well as increased bleeding times and reduced platelet 
aggregation in vitro (IoM, 2005). The Panel notes that these studies were uncontrolled for factors 
other than dietary n-3 LCPUFA which may have been responsible for the effects.  
The hypothesis that n-3 LCPUFA supplementation could modify platelet function, increase bleeding 
time and, eventually, increase the risk of spontaneous bleeding and haemorrhagic stroke, has been 
addressed in several controlled human intervention studies.  
Data on the effects of n-3 LCPUFA on the risk of haemorrhagic stroke are scarce. One open label 
human intervention study (Yokoyama et al., 2007) which investigated the effects of 1.8 g/day of EPA 
as ethyl esters consumed for five years in combination with statins (n=9,326) vs. statins alone 
(n=9,319) in hypercholesterolemic, high fish consumers on the primary and secondary prevention of 
coronary heart disease also assessed safety outcomes and the risk of stroke and its subclasses (Tanaka 
et al., 2008). Bleeding (cerebral and fundal bleedings, epistaxis, and subcutaneous bleeding 
combined) was more frequently reported in the EPA group than in controls. The Panel notes that nose 
or subcutaneous bleeding for example was self-reported, and that self-reported side effects are subject 
to high reporting bias in open label studies. The Panel also notes that no significant differences in the 
total incidence of stroke, or in the incidence of cerebral or subarachnoid haemorrhage, which were 
objectively assessed, were observed between groups. The Panel considers that intakes of EPA alone at 
doses up to 1.8 g/day for two years do not increase the risk of bleeding complications. 
Among the several prospective cohort studies published to date on the relationship between dietary 
intake of n-3 LCPUFA and risk of stroke, none has reported an increased risk of haemorrhagic stroke 
(He et al., 2002; IoM, 2005; Skerrett and Hennekens, 2003). Mean dietary intakes of n-3 LCPUFA at 
the highest quintiles of intake in these studies were <1 g/day.  
The Panel notes that there is no evidence for an increased risk of haemorrhagic stroke at doses of n-3 
LCPUFA which are usually consumed in Western diets, or at supplemental intakes of mostly EPA up 
to 1.8 g/day.   
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Some controlled human intervention studies on the effects of n-3 LCPUFA on bleeding complications 
other than haemorrhagic stroke have been conducted in population subgroups at high risk of bleeding, 
and which include patients on antiplatelet or antithrombotic medications (acetyl salicylic acid ASA, 
clopidogrel, anticoagulants) undergoing invasive procedures, and pregnant women at delivery.  
A Cochrane review (Hooper et al., 2004) including 48 radomised controlled trials (RCTs) conducted 
in subjects at high risk of cardiovascular events addressed the effects of n-3 LCPUFA at doses of 0.4 
to 7 g/day (compared to placebo or to a control oil) for at least six (and up to 47) months on 
CVD-related outcomes. The majority of subjects were under antithrombotic medications for the 
prevention or treatment of CVD. Seven of the studies, which used EPA and DHA at doses of 1.8 to 
6.9 g/day for 6 to 24 months, reported on bleeding episodes (Bairati et al., 1992; Eritsland et al., 1996; 
Franzen et al., 1993; Kaul et al., 1992; Leaf et al., 1994; Loeschke et al., 1996; Reis et al., 1991). No 
difference in the risk of bleeding between the intervention (n=17/949) and control (or placebo, 
n=13/836) groups was observed. The study which used the highest dose of n-3 LCPUFA (6.9 g/day) 
lasted six months (Leaf et al., 1994) and the study of longest duration (24 months) used 5.1 g/day of 
EPA and DHA (Loeschke et al., 1996). 
Harris (2007) reviewed 19 controlled intervention studies (4,397 subjects) in patients on secondary 
prevention for coronary heart disease (CHD) undergoing major vascular surgery or femoral puncture 
for diagnostic purposes who received EPA and DHA (1.4 to 6.9 g/day) from different sources (fish oil 
or capsules with EPA and DHA as triglycerides or ethyl esters) for 1-28 months. This review included 
six of the seven studies (all except Loeschke et al., 1996) considered by Hooper et al. (2004). Except 
in two studies (Nye et al., 1990; Rapp et al., 1991), subjects were on antithrombotic medications 
(ASA, warfarin or heparin). Even if these studies were not specifically designed to address the safety 
of n-3 LCPUFA, they all reported on adverse events in general and on bleeding complications in 
particular. None of the studies observed an increased frequency or severity of bleeding complications 
associated with EPA and DHA supplementation. Besides Leaf et al. (1994), the study using the 
highest dose of n-3 LCPUFA (6 g/day) lasted 4.5 months (Cairns et al., 1996) and the study of longest 
duration (28 months) used 4.8 g/day of EPA and DHA (Sacks et al., 1995).   
Also a recent meta-analysis of RCTs (Filion et al., 2010) on the effects of n-3 LCPUFA (EPA and 
DHA given at doses of 0.9-6.9 g/day for 1-55 months) on mortality (25 RCTs, mean duration 
12 months) and re-stenosis following angioplasty (14 RCTs, mean duration six months) in 
populations with (or at high risk of) CHD addressed safety outcomes, including bleeding. The risk of 
bleeding was not significantly different between the intervention and control groups in the 15 RCTs 
which reported on this outcome and entered data analysis. Of these, only four studies had not been 
considered by Harris (2007), three of which used either low doses (1 g/day) of n-3 LCPUFA (Rauch 
et al., 2010), had a very short duration (days) of the intervention (Calo et al., 2005) or included a 
small sample of patients (Rossing et al., 1996).  
Supplementation studies (n=31) with n-3 LCPUFA in patients (n=485) with end-stage renal disease 
undergoing dialysis and treated with antithrombotic medications (mostly ASA) which reported on 
bleeding complications were reviewed by Friedman and Moe (2006). Most studies were small 
(<20 subjects), uncontrolled or not randomised (n=21), lasted 4 to 24 weeks, and all except two 
(which provided EPA alone at doses of 1.8 and 3 g/day, respectively) used fish oil at doses of 1.4 to 
7.6 g/day. The RCTs had generally bigger sample sizes, were of longer duration ( 8 weeks) and used 
EPA or fish oil at doses of 1.8 to 5.2 g/day. Only one case of serious gastrointestinal bleeding 
required hospitalisation and was reported in one small uncontrolled study (n=7) in a patient 
consuming 3 g/day of EPA, but the event could not be attributed to the EPA treatment (Diskin et al., 
1990). There were no studies which reported on bleeding episodes using DHA in isolation at these 
dose levels. One single-arm intervention study was also available in children with end-stage renal 
disease on dialysis and at high risk of bleeding (Goren et al., 1991). A total of 16 children and 
adolescents (7 to 18 years) with hyperlipidaemia were given 3 to 8 g/day (weight-adjusted dose) of 
fish oil (0.3 to 2.4 g/day of EPA and DHA) for eight weeks, and were followed up for one month after 
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treatment. Platelet counts were normal in all subjects and mild side effects of treatment (abdominal 
cramps and diarrhoea which resolved spontaneously) did not include spontaneous bleeding.  
In a single-arm intervention (Sorgi et al., 2007), nine children and adolescents (8–16 years) under 
treatment for attention-deficit hyperactivity disorder (ADHD) received 30 mL of a liquid EPA/DHA 
which provided 16.2 g of n-3 LCPUFA (10.8 g EPA and 5.4 g DHA) per day for 4 weeks. Then doses 
were adjusted to maintain the AA:EPA ratio in the isolated plasma phospholipids between 1.5 and 3, 
so that three, two and four subjects consumed 8.1, 10.8 and 16.8 g/day, respectively, for another four 
weeks. No bleeding episodes were reported for any of the children during the eight-week study.  
No increased risk of bleeding complications at delivery was observed in pregnant women (n=533) 
who received 2.7 g/day n-3 LCPUFA from fish oil during the last trimester compared to olive oil or 
no supplement (Olsen et al., 1992).   
The Panel notes that some authoritative bodies have warned about an increased risk of bleeding 
complications at supplemental doses of these n-3 LCPUFAs of 3 g/day. The concern was raised by 
one human intervention study in children which reported nose bleeding episodes associated with the 
consumption of fish oil (Clarke et al., 1990).  
The study by Clarke et al. (1990) was a single-arm intervention on the effects of fish oil on blood 
lipids conducted in 11 children and adolescents with familial hyperlipoproteinaemia (aged 11 to 
21 years) who received an increasing dose of fish oil (18 % EPA and 12 % other n-3 fatty acids) for 
six months (starting at 1 g/day the first month and increasing by 1 g/day monthly up to 5 g/day) after 
three months of pre-treatment observation. Subjects were followed  after treatment for one month. 
Doses of EPA and DHA ranged from 0.3 to 1.5 g/day during the study. Eight of the 11 subjects 
reported nine episodes of epistaxis (nose bleeding) during the fish oil supplementation and none 
during the pre- and post-observation periods. In one case the intervention was stopped due to epistaxis 
with prolongation of bleeding time when doses of 1.5 g/day of EPA and DHA were being consumed. 
In two subjects, epistaxis was associated with modest prolongation of bleeding time (one subject was 
on ASA), whereas one subject who withdrew due to epistaxis had a normal bleeding time. One 
subject had asymptomatic occult blood in the stool on one occasion with normal bleeding time. 
Platelet counts, prothrombin and partial thromboplastin times were within the normal range. No 
information was provided in the publication about the time at which eight of the nine episodes of 
epistaxis occurred, nor about the dose of EPA and DHA being consumed at the time of the events. 
The Panel notes the uncontrolled nature and poor reporting of the study (e.g. medication use).  
The Panel notes that the bleeding episodes associated with the consumption of fish oil reported by 
Clarke et al. (1990) have not been observed in other studies of similar design conducted with higher 
doses of EPA and DHA in children at low (Sorgi et al., 2007) or high (Goren et al., 1991) risk of 
bleeding, or in a number of controlled intervention studies in adults at high risk of bleeding. 
The Panel considers that supplemental intakes of EPA and DHA combined of up to about 5 g/day for 
up to two years and up to about 7 g/day for up to six months, do not increase the risk of spontaneous 
bleeding episodes or bleeding complications, even in subjects at high risk of bleeding (e.g. taking 
acetylsalicylic acid or anti-coagulants). The Panel notes that the data available are insufficient to 
conclude on whether the same doses administered mostly as EPA or mostly as DHA would have 
different effects on this outcome. The Panel considers that intakes of EPA alone at doses up to 
1.8 g/day for two years do not increase the risk of bleeding complications.  
3.1.2. Bleeding time 
An increase in bleeding time beyond the normal range and/or leading to bleeding complications is 
considered an adverse effect. However, changes in bleeding time which are within the normal range 
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and which are not associated with bleeding complications may not be considered adverse. The 
predictive value of changes in bleeding time within the normal range in relation to bleeding 
complications is low.   
A number of small, short-term (4-11 weeks) controlled intervention studies have examined the effects 
of n-3 LCPUFA at doses of 2-15 g/day (most between 3 and 6 g/day) on bleeding time in healthy 
subjects and in subjects with hypercholesterolemia, hypertension, type 2 diabetes, patients with 
atherosclerosis undergoing coronary artery bypass graft surgery, or a combination of these, who were 
not under medications prolonging bleeding time, such as ASA or anti-coagulants (IoM, 2005). The 
majority of these studies reported a significant increase in bleeding time with n-3 LCPUFA 
supplementation (Cairns et al., 1996; Cobiac et al., 1991; DeCaterina et al., 1990; Emsley et al., 2008; 
Levinson et al., 1990; Lorenz et al., 1983; Mortensen et al., 1983; Sanders et al., 1981; Schmidt et al., 
1990; Smith et al., 1989; Thorngren and Gustafson, 1981; Wojenski et al., 1991; Zucker et al., 1988) 
whereas other studies using doses up to 6 g/day resulted in no difference (Blonk et al., 1990; Freese 
and Mutanen, 1997; Nelson et al., 1997; Rogers et al., 1987). All changes in bleeding times were 
within the normal range and did not lead to spontaneous bleeding. The Panel also notes that only a 
few studies have addressed the effects of supplements containing mostly EPA (Emsley et al., 2008; 
Wojenski et al., 1991) or mostly DHA (Nelson et al., 1997).  
Three of the studies specifically assessed dose-response relationships between n-3 LCPUFA intakes 
and bleeding time. Blonk et al. (1990) supplemented 45 healthy normotriglyceridaemic male 
volunteers with 1.5, 3 or 6 g/day of EPA and DHA as ethyl esters for 12 weeks. No significant effect 
on bleeding time was observed for any of the doses tested. Schmidt al. (1990) supplemented 
ten healthy males with increasing doses of n-3 LCPUFA (1.3 g, 4 g or 9 g/day) from fish oil daily for 
periods of six weeks each. Bleeding time increased significantly compared to baseline after the 4 g 
and the 9 g doses in a dose-dependent manner. A more recent intervention study (Cohen et al., 2011) 
examined the effects of increasing doses of EPA and DHA as ethyl esters (1, 2, 4 and 8 g/day for six 
consecutive weeks each, 24 weeks in total), either alone, in combination with ASA, or in combination 
with ASA plus clopidogrel, in 30 volunteers (ten subjects per group). Median bleeding times 
increased within the normal range in a dose-dependent manner with increasing doses of EPA and 
DHA given alone. No effect was reported in the ASA or the ASA plus clopidogrel groups which 
already had prolonged bleeding times.  
Four controlled studies (reviewed in VKM, 2011) assessed bleeding time in subjects supplemented 
with n-3 LCPUFA who were under ASA, and/or the international normalised ratio (INR) in subjects 
on warfarin as antithrombotic therapy at doses from 0.9 to 6.9 g/day (Bender et al., 1998; Dehmer et 
al., 1988; Eritsland et al., 1996; Leaf et al., 1994). Three studies observed no significant differences in 
bleeding times between the intervention group and controls, whereas the fourth study (Leaf et al., 
1994) did not compare the study groups directly. The Panel notes that n-3 LCPUFA supplementation 
did not lead to spontaneous bleeding or bleeding complications in any of the studies.   
The Panel notes that supplemental intakes of EPA and DHA combined of up to about 6 g/day do not 
enhance the effects of anti-platelet or antithrombotic medications on bleeding time, and that the 
changes in bleeding times within the normal range which have been observed in some intervention 
studies are not considered to be adverse as they were not associated with an increased risk of clinical 
complications (e.g. spontaneous bleeding). 
3.1.3. Platelet function 
Platelet dysfunction leading to bleeding complications is considered an adverse effect. However, 
changes in platelet function which are not associated with bleeding complications may not be 
considered adverse.  
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Several, mostly short-term, intervention studies have investigated the effects of n-3 LCPUFA on 
platelet function assessed by different methods and using a variety of outcome measures. 
Violi et al., (2010) recently reviewed published studies on the effects of EPA and DHA 
supplementation on platelet function. Among the 21 studies identified, only seven were controlled. Of 
these, three were conducted in healthy subjects and four in subjects with hypercholesteroaemia, 
hypertension, type 2 diabetes, or a combination of these. Doses of n-3 LCPUFA ranged from 
1 to 4 g/day and study duration from 30 days to one year. No effect of n-3 LCPUFA intake on platelet 
aggregation was observed in the two studies of shorter and longer duration, respectively, whereas five 
studies observed inhibition of platelet function or prolongation of platelet survival (study duration 
4-16 weeks). The effect on platelet function did not appear to be dose-dependent. Dose-response 
relationships between the intake of EPA and DHA and platelet aggregation, vWF, coagulation factors 
VII and VIII, AT III activity, protein C activity, plasma fibrinogen, fibronectin and fibrinolysis (PAI 
and t-PA ag) were specifically assessed in one study on ten healthy males supplemented with 1.3 g, 
4 g or 9 g of n-3 LCPUFA daily for periods of six weeks each (Schmidt et al., 1990). No significant 
effect of EPA and DHA was observed on platelet aggregation. Plasma fibrinogen decreased in a 
dose-dependent manner after intake of 1.3 g and 9 g of n-3 LCPUFA. The vWF decreased after the 
high dose, while plasma concentrations of factor VII, factor VIII, and AT III activity, protein C 
activity and fibronectin were unaltered by n-3 LCPUFA. At rest, PAI and t-PA ag. increased after 
intake of 9 g of n-3 LCPUFA, and PAI increased after n-3 LCPUFA ingestion in a dose-dependent 
fashion. The Panel notes that no effect on platelet aggregation was observed and that no 
dose-response relationship was reported between the intake of EPA and DHA and most of the 
variables related to blood coagulation.  
One of the studies specifically assessed whether DHA and EPA could have differential effects on 
platelet aggregation. In a double-blind placebo-controlled trial of parallel design, Woodman et al. 
(2003) randomised 59 treated hypertensive Type 2 diabetic men and postmenopausal women to 
4 g/day of EPA, DHA or olive oil (placebo) for six weeks. DHA but not EPA supplementation 
significantly reduced collagen aggregation (by 16.9 %) and TXB2 (by 18.8 %), whereas no significant 
changes were reported in either platelet activating factor (PAF)-stimulated platelet aggregation, 
fibrinolytic function or vascular function in either the EPA or DHA groups relative to placebo. 
However, another study comparing 4 g/day of EPA to the same amounts of n-3 LCPUFA (mostly 
EPA and DHA) from a fish oil concentrate given for four weeks found EPA to being more effective in 
decreasing platelet aggregation than fish oil concentrate (Wojenski et al., 1991). The Panel notes that 
available data on differential effects of EPA and DHA on platelet aggregation are scarce and 
inconsistent. 
The Panel notes that the changes on platelet function which are observed at supplemental intakes of 
EPA and DHA (either alone or in combination) up to about 4 g/day are not considered to be adverse 
as they are not associated with an increased risk of clinical complications (e.g. spontaneous bleeding). 
3.2. Glucose homeostasis 
Human intervention studies, mostly uncontrolled, have described adverse effects of supplemental 
n-3 LCPUFA ( 10 g/day) on glucose homeostasis, such as increased insulin requirements, an increase 
in glycated haemoglobin (HbA1c), and an increase in fasting and postprandial glycaemia, in patients 
with type 1 and type 2 diabetes (see De Caterina et al., 2007 for review). In 2005, the IoM advised 
that subjects with “impaired glucose tolerance or diabetic conditions requiring increased doses of 
hypoglycaemic agents” should take EPA and DHA supplements with caution (IoM, 2005).  
Data from (mostly controlled) human intervention studies with respect to the effects of n-3 LCPUFA 
supplementation on insulin requirements in type 1 diabetics, and on HbA1c and fasting/postprandial 
glycaemia/insulinaemia in type 2 diabetic subjects, have been recently reviewed in a number of 
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systematic reviews and meta-analyses (Balk et al., 2004; De Caterina et al., 2007; Farmer et al., 2001; 
Friedberg et al., 1998; Hartweg et al., 2008; 2009; Hendrich, 2010; MacLean et al., 2004; Montori et 
al., 2000).  
Doses of up to 5 g/day of n-3 LCPUFA given as triglycerides for 2-12 weeks do not appear to increase 
insulin requirements in subjects with type 1 diabetes, although the studies are small (De Caterina et 
al., 2007; Friedberg et al., 1998).  
With respect to subjects with type 2 diabetes, a Cochrane systematic review and meta-analysis 
performed in 2001 (Farmer et al., 2001) on the effects of fish oil in subjects with type 2 diabetes on 
different outcomes, including those related to glucose homeostasis, was updated in 2008 and 2009 
(Hartweg et al., 2008; 2009). The meta-analysis by Hartweg et al. (2008) included 23 trials 
(1,075 subjects, sample size range 8 to 418) where the majority of participants were male (age range 
21-85 years) with type 2 diabetes of 5-10 years duration under treatment with diet or oral 
hypoglycaemic agents, and generally with no diabetes-related complications. The mean dose of 
n-3 LCPUFA was 3.5 g/day, ranged from 1.7 to 10 g/day (from 1.08 to 5.2 g/day of EPA and from 
0.3 to 4.8 g/day of DHA), and the mean duration of treatment was 8.9 weeks. The EPA and DHA 
were given mostly in combination (two intervention arms gave EPA only and one DHA only) and in 
capsules. In most cases, controls received similar amounts of fat from vegetable oils (olive, sunflower, 
linseed, corn, safflower, and flaxseed). Linoleic acid, non-fat placebo, a saline solution, or usual diet 
served as control in the remaining studies (n=5). A total of 15 trials (n=848 subjects) reported on 
HbA1c, of which only four lasted at least 12 weeks, which is the time normally required to detect 
differences in HbA1c, and 11 lasted at least eight weeks, which may only allow detection of major 
changes in blood glucose control. A total of 21 trials reported fasting glucose concentrations, and the 
results could be pooled for 16 studies (n=930 subjects). Results from six of the eight studies reporting 
on fasting insulin concentrations could also be pooled. Supplementation with n-3 LCPUFA did not 
significantly affect HbA1c, fasting glucose or insulin concentrations. Similar results were obtained 
when seven new trials with a mean dose of 2.4 g/day (range 0.8 to 4.8 g/day) and mean duration of 
24 weeks were added to the analyses (Hartweg et al., 2009). More recent studies are in line with these 
results (Hendrich, 2010).  
Galgani et al. (2008) reviewed the effects of n-3 LCPUFA on insulin sensitivity in high-quality 
randomised intervention studies which used the euglycemic hyperinsulinemic clamp or the frequently 
sampled intravascular glucose tolerance test while controlling for the energy and macronutrient 
composition of the intervention and control diets. One study which met these requirements was 
published thereafter (Giacco et al., 2007). All studies used fish oil as a source of EPA and DHA and 
vegetable oils as control (olive oil, corn oil, safflower oil). Four studies (n=32 to 162) were conducted 
in healthy subjects using 2.4 to 3.6 g/day of EPA and DHA for 12-16 weeks. No effect of 
n-3 LCPUFA on insulin sensitivity was observed compared to the control oils (olive oil, corn oil). 
Five studies (n= 10 to 26) recruited subjects with type 2 diabetes and used EPA and DHA at doses of 
1.8 to 5 g/day and vegetable oils (olive oil, corn oil, safflower oil) as controls for 3-24 weeks. Only 
the study providing the highest dose of n-3 LCPUFA (5 g/day containing about 2.1 g EPA, 3.5 g DHA 
and 0.3 g DPA) for nine weeks (Mostad et al., 2006) reported a marginal decrease in glucose 
utilisation during the euglycemic hyperinsulinaemic clamp in the fish oil group (n=13) compared to 
the maize oil group (n=14; p=0.049) in a small sample of subjects. No significant changes in HbA1c 
were observed in this and other longer-term studies described above.  
The Panel notes that human intervention studies which have controlled for fat intake generally do not 
show a differential effect of vegetable oils and supplemental fish oil at doses up to 5 g/day of EPA 
and DHA consumed for 12 weeks on blood glucose control in diabetic subjects, or on insulin 
sensitivity in healthy or diabetic subjects.  
The Panel considers that supplemental intakes of EPA and DHA combined of up to 5 g/day consumed 
for up to 12 weeks do not significantly affect glucose homeostasis in healthy or diabetic subjects. The 
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Panel notes that the data available are insufficient to conclude on whether the same doses 
administered mostly as EPA or mostly as DHA would have different effects on this outcome.  
3.3. LDL-cholesterol concentrations in blood 
Several human intervention studies have addressed the effects of supplementation with n-3 LCPUFA 
on blood LDL-cholesterol concentrations. 
A meta-analysis of RCTs (Balk et al., 2006) pooled the results from 21 RCTs (about 8,000 subjects, 
37 intervention arms) conducted in healthy subjects; in subjects with diabetes, hypertension, or 
dyslipidemia; or in subjects with cardiovascular disease. Studies using >6 g/day of EPA + DHA or 
lasting <4 weeks were excluded. Due to the high number of studies found in the literature, a minimum 
sample size of 12 subjects per each n-3 LCPUFA intervention arm was required for inclusion. Doses 
of EPA and DHA ranged from 0.9 to 5.9 g/day (from fish oil or food) and the duration of the 
intervention was between 4 weeks and 2 years (17 studies lasted 6 months and 8 studies lasted 1 
year at doses of about 3.4 g/day). Study design was considerably heterogeneous. Random effects 
model meta-analyses found a significant increase in LDL cholesterol of +0.155 mmol/L (95 % CI 
+0.078 mmol/L, +0.207 mmol/L) compared to the control oils. In the majority of the studies, changes 
in LDL cholesterol associated with EPA and DHA intakes were <5 %. Earlier studies reported the 
highest increases in LDL-cholesterol. The Panel notes that these changes in LDL-cholesterol were 
accompanied by a significant decrease in TG (−0.31 mmol/L; 95 % CI −0.37 mmol/L, −0.23 mmol/L) 
and by a significant increase in HDL-cholesterol (+0.041 mmol/L; 95 % CI +0.021 mmol/L, 
+0.060 mmol/L), and that total blood cholesterol did not change significantly. Sensitivity analyses 
showed that dose of EPA and DHA and baseline concentrations of TG had a cumulative impact on the 
magnitude of changes in TG, but no influence on changes in HDL or LDL cholesterol, which 
appeared to be dose-independent.  
Since hypertriglyceridaemia is often observed in type 2 diabetes and this population subgroup is 
already at higher risk for CVD, an increase in LDL-cholesterol concentrations resulting from the 
treatment of elevated TG concentrations could be of particular concern in diabetic subjects. In the 
meta-analyses by Hartweg et al., (2008; 2009) that are described in Section 3.2, the effects of EPA 
and DHA supplementation on LDL-cholesterol concentrations were investigated in subjects with 
type 2 diabetes. Most studies provided EPA and DHA in combination at doses up to 6 g/day. Out of 
the 30 RCTs considered, 27 reported on LDL-cholesterol, 24 (n=1,530) on TG, 23 (n=1,533) on total 
cholesterol, 22 (n=1,443) on HLD-cholesterol, nine (n=637) on VLDL, five (n=476) on apoproteins 
A1 and B, and four (n=443) assessed LDL particle size. Compared to placebo (mostly vegetable oils), 
n-3 LCPUFA supplementation significantly increased LDL-cholesterol concentrations by 3 % (mean 
increase=+0.08 mmol/L). This effect was only observed at doses of >2 g/day of n-3 LCPUFA and was 
accompanied by a significant reduction in blood concentrations of TG of about 7 % (mean 
reduction=0.17 mmol/L), whereas no significant effect was reported on the remaining outcomes 
related to blood lipids, including total cholesterol concentrations.  
A recently published systematic review and meta-analysis of RCTs lasting four weeks or longer 
investigated whether these n-3 LCPUFA had different effects on blood lipids (Jacobson et al., 2012; 
Wei and Jacobson, 2011). Twelve studies used mostly DHA and four studies used mostly EPA. The 
control intervention in the studies using mostly DHA (from algal oils, 38 % DHA and 30 % saturated 
fatty acids, doses 0.7-3.0 g/day, mean=1.7 g/day) was either a control fat (olive oil, two studies) or a 
control diet, and lasted six weeks to three months (average seven weeks). In the studies comparing 
EPA (ethyl esters) to placebo or to a control intervention, the dose was always 1.8 g/day and EPA was 
given for three months to five years (average 12 weeks excluding the five-year study). The Panel 
notes that these studies may not have been appropriately controlled for other dietary components 
known to increase LDL-cholesterol concentrations (e.g. saturated fatty acids) and for the different 
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dose range of DHA and EPA used. The Panel considers that these studies do not allow conclusions to 
be drawn on the effects of EPA or DHA, or on the effects of EPA vs. DHA, on LDL cholesterol.  
In the same systematic review and meta-analysis (Jacobson et al., 2012; Wei and Jacobson, 2011), six 
studies which directly compared EPA (ethyl esters, >90 % EPA) with DHA (ethyl esters, >90 % 
DHA) used olive oil, safflower oil, corn oil or ALA as control fat, lasted 4-7 weeks, and administered 
EPA and DHA at doses between 2.3 and 4 g/day each. Control-adjusted changes in blood lipids were 
calculated for the EPA and DHA groups. DHA significantly increased LDL-cholesterol by 2.6 % 
compared to the control fat and by 3.3 % compared to EPA, which did not induce significant changes 
in LDL cholesterol (-0.7 %). The Panel notes that the observed increase in LDL cholesterol induced 
by DHA supplementation compared to the control fats was associated with a significant decrease in 
TG (-22.4 %) and with a significant increase in HDL-cholesterol (+7.3 %), and that non-HDL 
cholesterol was virtually not affected (-1.2 %). The Panel also notes that EPA supplementation did not 
have a significant effect on LDL- (-0.7 %) or HDL- (+1.4 %) cholesterol concentrations, and that 
these n-3 LCPUFAs appear to exert different effects on blood lipids.  
It has been suggested that n-3 LCPUFA may enhance transformation of TG-rich VLDL lipoproteins 
to cholesterol-rich LDL lipoproteins leading to a decrease in fasting TGs and to an increase in 
LDL-cholesterol by increasing particle size rather than particle number. These changes do not appear 
to be associated with an increase in total cholesterol or apolipoprotein B (VKM, 2011).  
The Panel notes that supplemental intakes of EPA and DHA combined of 2-6 g/day, and supplemental 
intakes of mostly DHA of 2-4 g/day, increase blood concentrations of LDL-cholesterol by about 3 %, 
and that such increase is accompanied by a decrease in TG with no changes in total (or non-HDL) 
cholesterol concentrations. The Panel also notes that supplemental intakes of mostly EPA at doses up 
to 4 g/day have no significant effect on LDL cholesterol concentrations. The Panel considers that the 
small increase in LDL-cholesterol concentrations associated with combined EPA and DHA 
supplementation or with DHA supplementation alone at the doses mentioned above may not be 
adverse in relation to CVD risk.  
3.4. Markers of lipid peroxidation 
Enhanced oxidative stress and increased lipid peroxidation occurring either locally in the vessel wall 
or systemically have been implicated in the pathogenesis of atherosclerosis in humans, although it is 
uncertain and poorly characterised whether, and the extent to which, changes in different markers of 
lipid peroxidation may modulate the risk of cardiovascular diseases independently of traditional risk 
factors. 
Early observations linking DHA intake with increased lipid peroxidation and oxidative damage to 
cells and molecules in laboratory animals may have been confounded by the presence of primary and 
secondary oxidation products in supplements lacking antioxidants. This effect was indeed reversed 
when DHA was administered with supplemental vitamin E (IoM, 2005; VKM, 2011). 
The majority of the human intervention studies considered below used fish oil stabilised with 
antioxidants, but some studies did not report whether sources of EPA, DHA, or both, contained 
antioxidants or not, whereas only a few studies reported on the concentration of primary and 
secondary oxidation products in the supplements administered. The Panel notes that the addition of 
antioxidants to food supplements containing n-3 LCPUFA to ensure product stability appears to be 
optional (GOED (Global Organisation for EPA and DHA Omega-3s), 2012). 
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3.4.1. F2-isoprostanes 
Some F2-isoprostanes assessed in urine or plasma (i.e. by immunometric assays or by 
mass-spectrometry) are reliable measures of in vivo lipid peroxidation. F2-isoprostanes are increased 
in association with a number of atherosclerotic risk factors, including cigarette smoking, 
hypercholesterolaemia, diabetes mellitus and obesity, among others. Also a reduction in 
cardiovascular risk factors is associated with a decrease in F2-isoprostanes formation in humans. 
However, the potential contribution of these compounds to the pathophysiology of vascular damage 
and atherosclerosis has not yet been defined (Minuz et al., 2006; Morrow, 2005; Patrignani and 
Tacconelli, 2005). 
A recent review identified nine controlled human intervention studies which used n-3 LCPUFA-rich 
oils stabilised with antioxidants, and mostly vegetable oils as control (olive, maize, sunflower, 
safflower or soy oil), and reported on plasma or urinary F2-isoprostanes (VKM, 2011). An additional 
study of more recent publications was identified by the Panel (Mas et al., 2010). Three studies were 
conducted in newborns (following maternal supplementation from 20 weeks of gestation until 
delivery with 4 g/day EPA and DHA from fish oil) (Barden et al., 2004), pre-term infants (EPA and 
DHA were incorporated to the pre-term formula; 5.25-8.75 mg/100 mL of formula) (Stier et al., 2001) 
or children with familial hypercholesterolaemia (9-19 years, 1.2 g/day DHA) (Engler et al., 2004). 
The remaining studies had recruited a variety of adults who were either healthy (e.g. young men, post-
menopausal women) or with various disease conditions (e.g. obesity, non insulin-dependent diabetes 
mellitus, hypertension, end-stage renal disease), and used either DHA alone (800 mg-4 g/day), EPA 
alone (1.6-4 g/day) or EPA and DHA in combination as fish oil (2-4 g/day) for three to six weeks. The 
studies of longer duration (six weeks) used the highest doses of EPA and DHA, both alone and in 
combination. Half of the studies reported a significant decrease in plasma or urinary concentrations of 
F2-isoprostanes in the n-3 LCPUFA group compared to controls (Barden et al., 2004; Higdon et al., 
2000; Mas et al., 2010; Mori et al., 2000; 2003), whereas the remaining studies did not observe 
significant changes between groups (Engler et al., 2004; Himmelfarb et al., 2007; Stier et al., 2001; 
Tholstrup et al., 2004; Wu et al., 2006). The Panel notes that the concentration of primary and 
secondary oxidation products in the oils used measured as peroxide value (PV) and anisidine value 
(AV) were reported only in a few studies. 
The Panel considers that supplemental intakes of EPA and DHA consumed either alone or in 
combination at doses up to about 4 g/day for six weeks do not induce lipid peroxidation as assessed 
by F2-isoprostanes.  
3.4.2. Oxidation of LDL particles 
As for F2-isoprostanes, oxidation of LDL particles has been associated with an increased risk of CVD 
in some studies, but the causality of such association has not been established. Oxidised LDL 
particles can be measured in blood directly by immunological methods, and their susceptibility to 
oxidation may be measured ex vivo after challenge with different pro-oxidant agents. The Panel notes 
that the latter is not an appropriate method to assess in vivo LDL peroxidation.    
Susceptibility of LDL to oxidation has been reported to be increased, decreased or unchanged during 
consumption of EPA and DHA from either fish oil or as ethyl esters, in a number of studies. Whereas 
an increased susceptibility of LDL to oxidation has been reported in some short-term studies 
(4-6 weeks), longer-term interventions (6-16 weeks) show no effect compared to control (mostly 
vegetable) oils at doses up to about 5 g/day (VKM, 2011).  
Two studies in which the diet was supplemented with salmon containing EPA and DHA 1.5 g/day and 
2.9 g/day (Seierstad et al., 2005) or herring containing EPA and DHA 1.2 g/day (Lindqvist et al., 
2009) did not show an effect of the intervention on plasma oxidised LDL concentrations compared to 
controls.  
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The Panel considers that supplemental intakes of EPA and DHA combined at doses up to about 
5 g/day consumed for up to 16 weeks do not induce sustained oxidative changes in circulating LDL 
particles. 
3.4.3. Other markers of lipid peroxidation 
Supplementation with EPA and DHA at doses up to 4.5 g/day has not been shown to affect other 
measures traditionally used to assess lipid peroxidation, such as thiobarbituric acid reactive 
substances (TBARS), malondialdehyde (MDA), conjugated diens or lipid hydroperoxides (VKM, 
2011). The Panel notes that these are not reliable markers of in vivo lipid peroxidation (EFSA Panel 
on Dietetic Products Nutrition and Allergies (NDA), 2011). 
3.4.4. Conclusion 
The Panel considers that supplemental intakes of EPA and DHA consumed either alone or in 
combination at doses up to about 5 g/day for up to 16 weeks do not induce changes in lipid 
peroxidation which might raise concern in relation to CVD risk as long as the oxidative stability of 
these n-3 LCPUFAs is guaranteed.  
3.5. Immune function 
Immunosuppression, if sustained, may increase the risk of infections. There are no human 
intervention studies available which have investigated the effects of n-3 LCPUFA supplementation on 
the risk of infections in vivo. There is some indication, from ex vivo and in vitro studies performed in 
peripheral white blood cells of human subjects consuming n-3 LCPUFA, that EPA and DHA may 
decrease the expression of cytokines and the proliferation of peripheral white blood cells at doses as 
low as 0.9 g/day EPA and 0.6 g/day DHA consumed as fish oil for 6-8 weeks (reviewed in IoM, 
2005). However, the clinical relevance of these changes in vivo is unknown.  
Chronic and/or inappropriate activation of inflammatory responses (innate immunity) can also lead to 
disease. However, there is no information available on the effect of high intakes of n-3 LCPUFA on 
the risk of chronic diseases of inflammatory origin. Some markers of the so-called low-grade systemic 
(e.g. high-sensitivity C-reactive protein, and some cytokines) and vascular (e.g., sICAM-1, VCAM-1, 
and E-selectin) inflammation have been associated with an increased risk of cardiovascular events in 
healthy and high-risk subjects. However, there is no evidence that changes induced by diet or drugs in 
any of these markers modify the risk of disease per se. Most of the intervention studies available 
(reviewed in VKM, 2011) which report on the effects of EPA and DHA on markers of systemic and 
vascular inflammation are small and generally not designed for that purpose. Although an increase in 
E-selectin and/or in sVCAM-1 has been reported in some studies at doses of EPA and DHA of about 
5 g/day, a recent meta-analysis of 18 randomised controlled trials found no effect of n-3 LCPUFA 
supplementation (dose 0.272 to 6.6 g/day) on these markers of vascular inflammation and a significant 
decrease in sICAM-1 (Yang et al., 2012). The majority of the studies report either no effect or a 
decrease in systemic markers of inflammation, including hs-CRP and TNF-alpha (Bloomer et al., 
2009; VKM, 2011).  
The Panel considers that supplemental intakes of EPA and DHA up to about 5 g/day are unlikely to 
induce changes in immune functions which might raise concern in relation to the risk of infections or 
inappropriate activation of inflammatory responses. The Panel notes that the data available are 
insufficient to conclude on whether the same doses administered mostly as EPA or mostly as DHA 
would have different effects on this outcome.  
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4. Derivation of a tolerable upper intake level (UL) 
The available data are not sufficient to establish a tolerable upper intake level for n-3 LCPUFA 
(DHA, EPA, and DPA, individually or combined) for any population group. 
5. Characterisation of the risk 
Mean dietary intake estimates of n-3 LCPUFA (EPA, DHA  DPA) from foods in European 
populations are up to 400-500 mg/day in adults and up to 324 mg/day in children. When supplements 
were included, or when only high consumers of fatty fish were considered, reported intakes in EU 
populations can be much higher, for example up to 2,570-2,700 mg/day in adults and up to 
400-600 mg/day in children (95 % percentile, 1,400-1,700 mg/day). The Panel notes that the studies 
reporting on high consumers of fish did not consider n-3 LCPUFA intakes from food supplements. 
The Panel notes that at observed intake levels, consumption of n-3 LCPUFA has not been associated 
with adverse effects in healthy children or adults.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and 
supplemental intakes of EPA alone up to 1.8 g/day, do not raise safety concerns for the adult 
population. Limited data are available on the effects of long-term supplementation with these n-3 
LCPUFAs at higher doses. The Panel also notes that observed intakes of EPA and DHA from food 
and food supplements in European populations are generally below these amounts. Dietary 
recommendations for EPA and DHA based on CVD risk considerations for European adults are 
between 250 and 500 mg/day. There are no specific recommendations for EPA. 
The Panel also considers that supplemental intakes of DHA alone up to about 1 g/day do not raise 
safety concerns for the general population. Limited data are available on the effects of long-term 
supplementation with DHA alone at higher doses. The Panel notes that specific dietary 
recommendations for DHA for European adults and children are well below this amount.  
No data are available for DPA when consumed alone. The Panel notes that in the majority of the 
human studies considered, fish oils, which also contained DPA in generally unknown (but relatively 
low) amounts, were the source of EPA and DHA. No dietary recommendations have been made 
specifically for DPA. 
CONCLUSIONS  
The Panel concludes that the available data are not sufficient to establish a tolerable upper intake 
level for n-3 LCPUFA (DHA, EPA, and DPA, individually or combined) for any population group.  
The Panel considers that supplemental intakes of EPA and DHA combined at doses up to 5 g/day, and 
supplemental intakes of EPA alone up to 1.8 g/day, do not raise safety concerns for the adult 
population. The Panel also considers supplemental intakes of DHA alone up to about 1 g/day do not 
raise safety concerns for the general population. No data are available for DPA when consumed alone. 
The Panel notes that in the majority of the human studies considered, fish oils, which also contained 
DPA in generally unknown (but relatively low) amounts, were the source of EPA and DHA.  
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APPENDICES 
A.  INTAKE OF LONG-CHAIN N-3 FATTY ACIDS (MG/DAY) AMONG ADULTS IN EUROPEAN COUNTRIES 
LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA Food Women Belgium 
(Sioen et al., 
2006) 2-day record 641 18 
 
39 
Data collected only on women in Ghent, 
Flanders 77.8 14.0 
 
427.7 
   
Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 29,017 50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
150.0 230.0 
 
   
France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 344 18 
 
44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  432.0 
   
      
630 18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  448.0 
   
EPA Food Men Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 24,786 50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
180.0 270.0 
 
   
France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 243 18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  456.0 
   
EPA Food 
Men 
and 
women France 
(Guevel et 
al., 2008) 
food frequency 
questionnaire n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake 141.0 140.0 
  
    
(Guevel et 
al., 2008) 
food frequency 
questionnaire n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study).Fifth quintile of EPA-
DHA intake 991.0 858.0 
  
    
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 126 65 > 65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  467.0 
   
   
Spain 
(Amiano et 
al., 2001) 
Diet history 
questionnaire 
(previous year) 26 35 
 
65 
Occasional fish consumers (<31 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 50.0 
   
      
24 35 
 
65 
Low fish consumers (32-64 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 130.0 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA Food 
Men 
and 
women Spain 
(Amiano et 
al., 2001) 
Diet history 
questionnaire 
(previous year) 27 35 
 
65 
Moderate fish consumers (65-115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 210.0 
   
      
25 35 
 
65 
High fish consumers (>115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 320.0 
   
EPA n.a. Women Finland 
(Suominen-
Taipale et 
al., 2010) 
food frequency 
questionnaire 166 n.a.   n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women. 200.0       
   
France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,785 35 > 35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 117.8 91.4 
 
308.5 
EPA n.a. Men Finland 
(Suominen-
Taipale et 
al., 2010) 
food frequency 
questionnaire 142 n.a. 
 
n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women. 300.0 
   
   
France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,099 45 > 45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 149.9 119.6 
 
375.1 
EPA 
Food and 
supplements Women 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary) 6258 39   78 Fish-eaters in the EPIC-Norfolk cohort 110.0       
EPA 
Food and 
supplements Men 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary) 5,952 39 
 
78 Fish-eaters in the EPIC-Norfolk cohort 130.0 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA 
Food and 
supplements 
Men 
and 
women Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 3,144 16   79 National survey NORKOST 1997 330.0       
DPA Food Women Belgium 
(Sioen et al., 
2006) 2-day record 641 18   39 
Data collected only on women in Ghent, 
Flanders 25.3 11.7   100.2 
      Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 29,017 50   64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997   60.0 90.0   
      France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 344 18   44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  126.0       
            630 18   64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  127.0       
DPA Food Men Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 24,786 50   64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997   80.0 100.0   
      France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 243 18   64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  129.0       
DPA Food 
Men 
and 
Women France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 126 65 > 65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  125.0       
DPA n.a. Women France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,785 35 > 35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 55.9 50.2   109.1 
DPA n.a. Men France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,099 45 > 45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 74.8 68.2   138.4 
DPA 
Food and 
supplements 
Men 
and 
Women Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 3,144 16   79 National survey NORKOST 1997 70.0       
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
DHA Food Women Belgium 
(Sioen et al., 
2006) 2-day record 641 18   39 
Data collected only on women in Ghent, 
Flanders 131.2 42.5   647.1 
   
Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 29,017 50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
360.0 520.0 
 
   
France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 344 18 
 
44 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  757.0 
   
      
630 18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  776.0 
   
DHA Food Men Denmark 
(Joensen et 
al., 2010) 
food frequency 
questionnaire 24,786 50 
 
64 
Data of the Danish Diet, Cancer and 
Health cohort study, collected on 
volunteers living in Copenhagen or 
Aarhus. Recruitment 1993-1997 
 
430.0 630.0 
 
   
France 
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 243 18 
 
64 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  797.0 
   
DHA Food 
Men 
and 
women France 
(Guevel et 
al., 2008) 
food frequency 
questionnaire n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake 251.0 260.0 
  
   
France 
(Guevel et 
al., 2008) 
food frequency 
questionnaire n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study). Fifth quintile of EPA-
DHA intake 1,709.0 1,434.0 
  
    
(Bemrah et 
al., 2009) 
food frequency 
questionnaire 126 65 > 65 
French high seafood consumers 
(CALIPSO study). N-3 consumption 
from seafood (not from the total diet)  819.0 
   
   
Spain 
(Amiano et 
al., 2001) 
Diet history 
questionnaire 
(previous year) 26 35 
 
65 
Occasional fish consumers (<31 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 190.0 
   
      
24 35 
 
65 
Low fish consumers (32-64 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 440.0 
   
      
27 35 
 
65 
Moderate fish consumers (65-115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 580.0 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
DHA Food 
Men 
and 
women Spain 
(Amiano et 
al., 2001) 
Diet history 
questionnaire 
(previous year) 25 35 
 
65 
High fish consumers (>115 g/d). 
Adjusted for energy intake. Data on n-3 
fatty acid intake collected in the EPIC 
cohort of Gipuzkoa (Basque Country) 850.0 
   
DHA n.a. Women Finland 
(Suominen-
Taipale et 
al., 2010) 
food frequency 
questionnaire 166 n.a.   n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women. 600.0       
   
France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,785 35 > 35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 225.9 177.0 
 
574.2 
DHA n.a. Men Finland 
(Suominen-
Taipale et 
al., 2010) 
food frequency 
questionnaire 142 n.a. 
 
n.a. 
Finnish maritime and freshwater area 
fishermen, their wives and other family 
members of a sub-group (living near 
Helsinki) of the Fishermen Study 
population. Mean age of the full study 
(n=1410): 47 y (SE: 0,5) for men, 46 
(SE: 0,5) for women. 700.0 
   
   
France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2,099 45 > 45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 272.6 221.3 
 
668.4 
DHA 
Food and 
supplements Women 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary) 6258 39   78 Fish-eaters in the EPIC-Norfolk cohort 150.0       
DHA 
Food and 
supplements Men 
United-
Kingdom 
(Welch et al., 
2010) 
7-day record (24-h 
recall and 6-day 
diary) 5,952 39 
 
78 Fish-eaters in the EPIC-Norfolk cohort 190.0 
   
DHA 
Food and 
supplements 
Men 
and 
women Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 3,144 16   79 National survey NORKOST 1997 490.0       
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA+ 
DHA Food Women Belgium 
(Sioen et al., 
2010) 
food frequency 
questionnaire 19 18   39 
Non-consumers of n-3 foods and 
supplements. Data collected from a 
convenience sample (relatives, friends 
and colleagues) of women living in 
Flanders 181.0 118.0     
        
(Sioen et al., 
2006) 2-day record 641 18   39 
Data collected only on women in Ghent, 
Flanders 208.9 54.1   1,115.4 
   
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls 347 19   30 National Dutch survey 2007-2010   75.0 133.0 285.0 
            351 31   50 National Dutch survey 2007-2010   89.0 155.0 330.0 
            353 51   69 National Dutch survey 2007-2010   107.0 185.0 388.0 
EPA+ 
DHA Food Men 
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls 356 19   30 National Dutch survey 2007-2010   77.0 139.0 305.0 
            348 31   50 National Dutch survey 2007-2010   95.0 169.0 364.0 
            351 51   69 National Dutch survey 2007-2010   110.0 194.0 414.0 
EPA+ 
DHA Food 
Men 
and 
women France 
(Guevel et 
al., 2008) 
food frequency 
questionnaire n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study). First quintile of EPA-
DHA intake 392.0 405.0     
            n.a. 18 > 65 
French high seafood consumers 
(CALIPSO study). Fifth quintile of EPA-
DHA intake 2,700.0 2,324.0     
EPA+ 
DHA 
Food 
(without 
fortified 
food) Women Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks) 181 18   24 National German survey 1998 126.6 83.9   367.8 
            396 25   34 National German survey 1998 167.4 121.2   501.0 
            399 35   44 National German survey 1998 196.6 147.2   471.8 
      
319 45   54 National German survey 1998 207.1 160.3   578.3 
            369 55   64 National German survey 1998 218.9 172.4   560.1 
            408 65   79 National German survey 1998 199.9 158.4   556.3 
EPA+ 
DHA 
Food 
(without 
fortified 
food) Men Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks) 189 18   24 National German survey 1998 232.1 153.9   790.3 
            412 25   34 National German survey 1998 212.0 161.7   553.2 
            411 35   44 National German survey 1998 238.3 181.8   643.5 
            321 45   54 National German survey 1998 295.0 216.5   826.6 
            353 55   64 National German survey 1998 274.4 195.1   794.5 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA+ 
DHA 
Food 
(without 
fortified 
food) Men Germany 
(Bauch et al., 
2006) 
Dietary history 
(last 4 weeks) 271 65   79 National German survey 1998 277.7 204.1   668.3 
EPA+ 
DHA 
Food and 
supplements Women Belgium 
(Sioen et al., 
2010) 
food frequency 
questionnaire 5 18   39 
Breasfeeding women. Data collected 
from a convenience sample (relatives, 
friends and colleagues) of women living 
in Flanders 299.0 205.0     
            18 18   39 
Pregnant women. Convenience sample, 
in Flanders 328.0 232.0     
            19 18   39 
Supplement users. Convenience sample, 
in Flanders 1,067.0 998.0     
            395 18   39 
Consumers of n-3 foods. Convenience 
sample, in Flanders 281.0 209.0     
            414 18   39 
Total population. Convenience sample, 
in Flanders 276.0 199.0     
   
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls 347 19   30 National Dutch survey 2007-2010   76.0 133.0 296.0 
            351 31   50 National Dutch survey 2007-2010   100.0 189.0 488.0 
      
353 51   69 National Dutch survey 2007-2010   133.0 264.0 611.0 
EPA+ 
DHA 
Food and 
supplements Men 
The 
Netherlands 
(van Rossum 
et al., 2011) 
two non-
consecutive 24-
hour dietary recalls 356 19   30 National Dutch survey 2007-2010   75.0 137.0 312.0 
            348 31   50 National Dutch survey 2007-2010   97.0 179.0 416.0 
            351 51   69 National Dutch survey 2007-2010   131.0 239.0 513.0 
EPA+ 
DHA 
Food and 
supplements 
Men 
and 
women Ireland 
(Leite et al., 
2010) 7-day record 1097 18   64 
Non under-reporters. North/South Ireland 
food consumption survey 275.0 124.0   1,147.0 
      
424 18   35 
Non under-reporters. North/South Ireland 
food consumption survey 187.0 99.0   825.0 
            422 36   50 
Non under-reporters. North/South Ireland 
food consumption survey 297.0 133.0   1,160.0 
            251 51   64 
Non under-reporters. North/South Ireland 
food consumption survey 386.0 179.0   1,278.0 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
EPA+ 
DHA Supplements Women Austria 
(Elmadfa et 
al., 2009) 
Quantitative 
consumption 
frequency 
questionnaire 6 18   65 
Data collected on consumption of dietary 
supplements among 282 adults in all 
Austria (77 supplements users)   268.0 738.0   
EPA+ 
DHA Supplements Men Austria 
(Elmadfa et 
al., 2009) 
Quantitative 
consumption 
frequency 
questionnaire 5 18   65 
Data collected on consumption of dietary 
supplements among 282 adults in all 
Austria (77 supplements users)   557.0 1,000.0   
EPA+ 
DPA+ 
DHA n.a. Women France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2785 35 > 35 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 399.6 320.6   980.2 
EPA+ 
DPA+ 
DHA n.a. Men France 
(Astorg et 
al., 2004) 
at least ten 24-hour 
recalls 2785 45 > 45 
Data from the Su.Vi.Max cohort Study 
(inclusion in 1994-19695, follow-up of 8 
years), collected from at least ten 24-hour 
recalls over a period of 2.5 years, 
between the inclusion and 1998. Age at 
inclusion: 45-63 y (men), 35-63 y 
(women) 497.3 408.3   1,159.3 
EPA+ 
DPA+ 
DHA 
Food and 
supplements Women Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 406 16 
 
79 
First quartile of long chain n-3 fatty 
acids. National survey NORKOST 1997 130.0 
   
      
406 16 
 
79 
Fourth quartile of long chain n-3 fatty 
acid intake. National survey NORKOST 
1997 1,730.0 
   EPA+ 
DPA+ 
DHA 
Food and 
supplements Men Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 379 16 
 
79 
First quartile of long chain n-3 fatty 
acids. National survey NORKOST 1997 190.0 
   
      
378 16 
 
79 
Fourth quartile of long chain n-3 fatty 
acid intake. National survey NORKOST 
1997 2,570.0 
   EPA+ 
DPA+ 
DHA 
Food and 
supplements 
Men 
and 
women Norway 
(Johansson 
et al., 1998) 
food frequency 
questionnaire 3144 16 
 
79 National survey NORKOST 1997 890.0 
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LCn-3 
PUFA 
Nutrient 
source Sex Country Reference Dietary method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included 
or excluded mean median P75 P95 
LC n-3 
PUFA 
Food 
(including 
fish oil) Women Iceland 
(Steingrímsd
óttir et al., 
2003) 24-hour recall 
n.a. (total 
female 
sample 
15-80 y: 
662) 20   39 National Icelandic survey 300.0       
            
n.a. (total 
female 
sample 
15-80 y: 
662) 40   59 National Icelandic survey 600.0       
            
n.a. (total 
female 
sample 
15-80 y: 
662) 60   80 National Icelandic survey 900.0       
LC n-3 
PUFA 
food 
(including 
fish oil) Men Iceland 
(Steingrímsd
óttir et al., 
2003) 24-hour recall 
n.a. (total 
male 
sample 
15-80 y: 
580) 20   39 National Icelandic survey 700.0       
            
n.a. (total 
male 
sample 
15-80 y: 
580) 40   59 National Icelandic survey 1,100.0       
            
n.a. (total 
male 
sample 
15-80 y: 
580) 60   80 National Icelandic survey 1,300.0       
LC n-3 
PUFA 
food 
(including 
fish oil) 
Men 
and 
women Iceland 
(Steingrímsd
óttir et al., 
2003) 24-hour recall 1242 15   80 National Icelandic survey 700.0       
n.a.: not available 
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B.  INTAKE OF LONG-CHAIN N-3 FATTY ACIDS (MG/DAY) AMONG CHILDREN IN EUROPEAN COUNTRIES 
LCn-
3PUFA 
Nutrient 
source Sex Country Reference 
Dietary 
method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded mean median P75 P95 
EPA Food 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food) 661 2.5 
 
6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.  25.0 
 
21.0 
 
EPA n.a. 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007b) 7-day record 341 13   18 
Data collected in the region of Ghent in 
Flanders 55.9 25.4   244.2 
EPA 
Food and 
supplements 
Boys 
and 
girls Sweden 
(Enghardt 
Barbieri et al., 
2006) 4-day record 590 4   4 National survey 40.0 10.0   140.0 
      
889 8 
 
9 National survey 40.0 20.0 
 
170.0 
            
1,01
6 11   12 National survey 40.0 20.0   160.0 
DPA Food 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food) 661 2.5   6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.  10.0   10.0   
DPA n.a. 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007b) 7-day record 341 13   18 
Data collected in the region of Ghent in 
Flanders 18.4 9.6   62.5 
DPA 
Food and 
supplements 
Boys 
and 
girls Sweden 
(Enghardt 
Barbieri et al., 
2006) 4-day record 590 4   4 National survey 30.0 20.0   70.0 
            889 8   9 National survey 40.0 30.0   90.0 
            
1,01
6 11   12 National survey 40.0 30.0   90.0 
DHA Food 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007a) 
3-day record 
(food) 661 2.5 
 
6.5 
No consumption of supplements 
containing PUFA. Data collected in 
Flanders.  47.0 
 
46.0 
 
DHA n.a. 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007b) 7-day record 341 13   18 
Data collected in the region of Ghent in 
Flanders 111.4 72.4   363.2 
DHA 
Food and 
supplements 
Boys 
and 
girls Sweden 
(Enghardt 
Barbieri et al., 
2006) 4-day record 590 4   4 National survey 100.0 60.0   320.0 
      
889 8 
 
9 National survey 120.0 80.0 
 
420.0 
 
          
1,01
6 11   12 National survey 120.0 70.0   420.0 
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LCn-
3PUFA 
Nutrient 
source Sex Country Reference 
Dietary 
method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded mean median P75 P95 
EPA+ 
DHA Food Girls 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls 151 7   8 National survey   63.0 112.0 243.0 
            352 9   13 National survey   65.0 119.0 251.0 
            354 14   18 National survey   69.0 122.0 263.0 
    Boys 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls 153 7   8 National survey   48.0 88.0 200.0 
            351 9   13 National survey   56.0 102.0 230.0 
            352 14   18 National survey   65.0 118.0 263.0 
EPA+ 
DHA n.a. 
Boys 
and 
girls Belgium 
(Sioen et al., 
2007b) 7-day record 341 13   18 
Data collected in the region of Ghent in 
Flanders 167.3 96.9   603.0 
EPA+ 
DHA 
Food 
(without 
fortified 
food) Girls Germany 
(Sichert-Hellert 
et al., 2009) 
yearly 3-day 
dietary records 241 2 < 4 
fish consumers. Data from the DONALD 
cohort, from 7152 records of 1024 
subjects living in/near Dortmund. Mean 
number of repeated 3-day records: 7.  
In 2717 3-day records, i.e. on 3018 single 
days, fish consumption was documented. 100.0       
            241 2 < 4 
on days with fish consumption. Data from 
the DONALD cohort 245.0       
            330 4   6 fish consumers.  135.0       
            330 4   6 on days with fish consumption. 335.0       
            294 7   9 fish consumers 181.0       
            294 7   9 on days with fish consumption 438.0       
            213 10   12 fish consumers 188.0       
            213 10   12 on days with fish consumption 473.0       
            113 13   14 fish consumers 214.0       
            113 13   14 on days with fish consumption 536.0       
            132 15   18 fish consumers 264.0       
            132 15   18 on days with fish consumption 685.0       
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LCn-
3PUFA 
Nutrient 
source Sex Country Reference 
Dietary 
method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded mean median P75 P95 
EPA+ 
DHA 
Food 
(without 
fortified 
food) Boys Germany 
(Sichert-Hellert 
et al., 2009) 
yearly 3-day 
dietary records 236 2 < 4 
fish consumers. Data from the DONALD 
cohort, from 7152 records of 1024 
subjects living in/near Dortmund. Mean 
number of repeated 3-day records: 7.  
In 2717 3-day records, i.e. on 3018 single 
days, fish consumption was documented. 118.0       
            236 2 < 4 on days with fish consumption 289.0       
            352 4   6 fish consumers 142.0       
            352 4   6 on days with fish consumption 359.0       
            306 7   9 fish consumers 168.0       
            306 7   9 on days with fish consumption 433.0       
      
220 10   12 fish consumers 206.0       
            220 10   12 on days with fish consumption 528.0       
            128 13   14 fish consumers 324.0       
            128 13   14 on days with fish consumption 838.0       
            152 15   18 fish consumers 301.0       
            152 15   18 on days with fish consumption 763.0       
EPA+ 
DHA 
Food and 
supplements Girls 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls 151 7   8 National survey   66.0 120.0 294.0 
            352 9   13 National survey   66.0 117.0 264.0 
            354 14   18 National survey   71.0 126.0 282.0 
EPA+ 
DHA 
Food and 
supplements Boys 
The 
Netherlands 
(van Rossum et 
al., 2011) 
2 non-
consecutive 24-
hour dietary 
recalls 153 7   8 National survey   62.0 122.0 314.0 
            351 9   13 National survey   65.0 126.0 317.0 
            352 14   18 National survey   67.0 124.0 295.0 
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LCn-
3PUFA 
Nutrient 
source Sex Country Reference 
Dietary 
method n 
Age 
min 
 
Age 
max 
Population / Fortified foods included or 
excluded mean median P75 P95 
EPA+ 
DPA+ 
DHA 
Food 
(without 
fortified 
food) 
Boys 
and 
girls Norway (VKM, 2011) 
semi-
quantitative 
FFQ 
1,23
1 1   1 National survey. Non breast-fed children. 100.0     400.0 
     
semi-
quantitative 
FFQ 
1,72
0 2 
 
2 National survey 200.0 
  
700.0 
     
4-day record 391 4 
 
4 National survey 200.0 
  
600.0 
     
4-day record 815 9 
 
9 National survey 200.0 
  
700.0 
     
4-day record 
1,00
9 13 
 
13 National survey 200.0     700.0 
EPA+ 
DPA+ 
DHA 
Food and 
supplements 
Boys 
and 
girls Norway (VKM, 2011) 
semi-
quantitative 
FFQ 
1,23
1 1   1 National survey. Non breast-fed children. 400.0     1,400.0 
     
semi-
quantitative 
FFQ 
1,72
0 2 
 
2 National survey 600.0 
  
1,700.0 
     
4-day record 391 4 
 
4 National survey 400.0 
  
1,400.0 
     
4-day record 815 9 
 
9 National survey 300.0 
  
1,200.0 
     
4-day record 
1,00
9 13   13 National survey 300.0     1,100.0 
LC n-3 
PUFA 
Food 
(including 
fish oil) Girls Iceland 
(Steingrímsdótti
r et al., 2003) 24-hour recall n.a. 15   19   200.0       
    Boys Iceland 
(Steingrímsdótti
r et al., 2003) 24-hour recall n.a. 15   19   400.0       
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C.  INTAKE OF LONG-CHAIN n-3 FATTY ACIDS (% E) AMONG CHILDREN 
LCn-
3PUFA 
Nutrient 
source Sex Country Reference 
Dietary 
method n 
Age 
min 
Age 
max 
Population / Fortified 
foods included or 
excluded mean median P75 P95 
EPA Food 
Boys and 
girls Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food) 661 2.5 6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.  0.02   0.01   
  n.a. 
Boys and 
girls Belgium 
(Sioen et 
al., 2007b) 
7-day 
record 341 13 18 
Data collected in the 
region of Ghent in 
Flanders 0.02 0.01   0.09 
DPA Food 
Boys and 
girls Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food) 661 2.5 6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.  0.01 
 
0.01 
 
 
n.a. 
Boys and 
girls Belgium 
(Sioen et 
al., 2007b) 
7-day 
record 341 13 18 
Data collected in the 
region of Ghent in 
Flanders 0.01 0 
 
0.03 
DHA Food 
Boys and 
girls Belgium 
(Sioen et 
al., 2007a) 
3-day 
record 
(food) 661 2.5 6.5 
No consumption of 
supplements containing 
PUFA. Data collected in 
Flanders.  0.03   0.03   
  n.a. 
Boys and 
girls Belgium 
(Sioen et 
al., 2007b) 
7-day 
record 341 13 18 
Data collected in the 
region of Ghent in 
Flanders 0.05 0.03   0.15 
EPA+ 
DHA n.a. 
Boys and 
girls Belgium 
(Sioen et 
al., 2007b) 
7-day 
record 341 13 18 
Data collected in the 
region of Ghent in 
Flanders 0.07 0.04   0.26 
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GLOSSARY AND ABBREVIATIONS 
AA  Arachidonic acid  
ADHD  Attention-deficit hyperactivity disorder 
ALA  -linoleic acid 
ANSES Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du 
travail 
ASA  Acetylsalicylic acid 
AT  Antithrombin 
AV  Anisidine value 
BfR  Bundesinstitut fur Risikobewertung 
CHD  Coronary heart disease 
CRP  C-reactive protein 
CSS  Conseil Supérieur de la Santé 
CVD  Cardiovascular disease 
D-A-CH Deutschland-Austria-Confoederatio Helvetica 
DHA  Docosahexaenoic acid 
DoH  Department of Health 
DPA  Docosapentaenoic acid 
EPA  Eicosapentaenoic acid 
FA  Fatty Acid 
FAO  Food and Agriculture Organization 
FDA  Food and Drug Administration 
GOED  Global Organisation for EPA and DHA Omega-3s 
GRAS  Generally recognised as safe 
HbA1c  Glycated haemoglobin 
HDL  High density lipoprotein 
hs-CRP  High-sensitivity C-reactive Protein 
INR  International normalised ratio 
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IoM  Institute of Medecine 
LCPUFA Long chain polyunsaturated fatty acids 
LDL  Low density lipoprotein 
MD  Malondialdehyde 
NNR  Nordic Nutrition Recommendations 
PAI  Plasminogen activator inhibitor 
PAF  Platelet activating factor  
PV  Peroxide value 
PUFA  Polyunsaturated fatty acids  
RCTs  Randomised control trials 
SACN  Scientific Advisory Committee on Nutrition 
SHC  Superior Health Council 
sICAM-1 Soluble intercellular adhesion molecule-1 
TAGs  Triacylglycerols 
TBARS Thiobarbituric acid reactive substances 
TG  Triglycerides 
TXB2  Thromboxane B2 
TNF-alpha Tumor necrosis factor-alpha  
t-PA ag  Tissue plasminogen activator antigen 
UL  Tolerable Upper Intake Level 
VCAM-1 Vascular cell adhesion molecule-1 
VKM  Norwegian Scientific Committee for Food Safety 
vWF  von Willebrand factor 
WHO  World Health Organization 
